Lopixibat

Lopixibat Uses, Dosage, Side Effects, Food Interaction and all others data.

Lopixibat is under investigation in clinical trial NCT03905330 (A Study to Evaluate the Efficacy and Safety of Lopixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)).

Trade Name	Lopixibat
Availability	Prescription only
Generic	Maralixibat
Maralixibat Other Names	Lopixibat, Lum-001 cation, Lum001 cation, Maralixibat, Maralixibat cation
Related Drugs	Livmarli
Type
Formula	C₄₀H₅₆N₃O₄S
Weight	Average: 674.96 Monoisotopic: 674.398604889
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Lopixibat multivitamins interaction

[Moderate] Lopixibat may affect the absorption of fat-soluble vitamins (FSV) including A, D, E, and K.

In a clinical study, emergent FSV deficiency was reported in 10% of patients during 48 weeks of treatment.

In addition, it should be noted that patients with Alagille syndrome (ALGS) can have FSV deficiency at baseline.

Clinical and laboratory monitoring of serum FSV levels is recommended at baseline and during treatment with maralixibat.

If FSV deficiency is diagnosed, supplementation with FSV should be initiated.

If FSV deficiency persists or worsens despite adequate FSV supplementation, discontinuation of maralixibat should be considered.